<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2208234024
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2010
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        AGGRASTAT 0.25MG/ML I.V. VIAL
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        TIROFIBAN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        0.25
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Concentrate for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        980.15
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Patheon Manufacturing Services LLC " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Patheon Manufacturing Services LLC 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 530]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Salehiya Trading Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Algorithm SAL
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        B01AC17
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Aggrastat is used to help assist the blood flow to your heart and to help prevent chest pain and heart</p><p>attacks. It works by preventing platelets, cells found in the blood, from forming blood clots.</p><p>This medicine may also be used in patients whose heart vessels are dilated with a balloon</p><p>(percutaneous coronary intervention or PCI). This is a procedure, possibly with implantation of a small tube (stent), to improve the blood flow to the heart.</p><p>Aggrastat is intended for use with aspirin and unfractionated heparin.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Aggrastat</strong></p><p>&bull; if you are allergic (hypersensitive) to tirofiban or any of the other ingredients of Aggrastat (listed in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>&nbsp; &nbsp;Section 6 &ldquo;What Aggrastat contains&rdquo;</p><p>&bull; if you are bleeding internally or have a history of bleeding internally within the last 30 days.</p><p>&bull; if you have a history of bleeding in the brain, brain tumor or abnormal blood vessels in the brain.</p><p>&bull; if you have severe uncontrolled high blood pressure (malignant hypertension).</p><p>&bull; if you have a low blood platelet count (thrombocytopenia) or problems with blood clotting.</p><p>&bull; if you developed thrombocytopenia if you had received treatment with Aggrastat or another medicine&nbsp;&nbsp;&nbsp;</p><p>&nbsp; &nbsp;in the same group of drugs previously.</p><p>&bull; if you have a history of stroke within the last 30 days or any history of stroke with bleeding.</p><p>&bull; if you have been seriously injured or had a major operation within the last 6 weeks.</p><p>&bull; if you have severe liver disease.</p><p>Your doctor will review your medical history to see if you are at an increased risk of any side effects associated with being given this medicine.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor before using Aggrastat, if you have or have had:</p><p>&bull; any medical problems</p><p>&bull; any allergies</p><p>&bull; cardiopulmonary resuscitation (CPR), a biopsy, or a procedure to break up kidney stones within the</p><p>&nbsp; &nbsp;last 2 weeks</p><p>&bull; been seriously injured or had a major operation within the last 3 months</p><p>&bull; an ulcer in the stomach or intestine (duodenum) within the last 3 months</p><p>&bull; a recent bleeding disorder (within 1 year) such as bleeding in the stomach or intestine, or blood in&nbsp;</p><p>&nbsp; &nbsp;your urine or stool</p><p>&bull; recent spinal procedure</p><p>&bull; a history or symptoms of splitting of the aorta (aortic dissection)</p><p>&bull; uncontrolled high blood pressure (hypertension)</p><p>&bull; an inflammation of the lining around your heart (pericarditis)</p><p>&bull; an inflammation of the blood vessels (vasculitis)</p><p>&bull; problems with the blood vessels in the back of your eye (retina)</p><p>&bull; treatment with medications that help to prevent or dissolve blood clots</p><p>&bull; kidney problems</p><p>&bull; a special intravenous line inserted under your collar bone within the last 24 hours</p><p>&bull; heart failure</p><p>&bull; very low blood pressure due to a failing heart (cardiogenic shock)</p><p>&bull; a liver disorder</p><p>&bull; low blood count or anemia</p><p>&nbsp;</p><p><strong>Other medicines and Aggrastat</strong></p><p>In general, Aggrastat can be used with other medicines. Please tell your doctor if you are taking or have recently taken or might take any other medicines, including medicines obtained without a prescription, as some drugs may affect each other&rsquo;s action. It is especially important to tell your doctor if you are taking other medicines that help prevent your blood from clotting such as warfarin.</p><p>&nbsp;</p><p><strong>Aggrastat with food and drink</strong></p><p>Food and drink have no effect on this medicine.</p><p>&nbsp;</p><p><strong>Pregnancy and breastfeeding</strong></p><p>If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before using this medicine.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Due to your disease state, you will not be able to drive or operate machinery while Aggrastat is being used.</p><p>&nbsp;</p><p><strong>Aggrastat contains sodium</strong></p><p>This medicinal product contains approximately 189 mg of sodium per 50 ml vial which should be taken into consideration by patients on a controlled sodium diet.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Aggrastat should be prescribed by a qualified doctor who is experienced in the management of heart attacks.</p><p>You have been given, or are about to be given, Aggrastat into a vein. Your doctor will decide on the appropriate dose, depending on your condition and your weight.</p><p>&nbsp;</p><p><strong>Use in Children</strong></p><p>The use in children is not recommended.</p><p>&nbsp;</p><p><strong>If you use more Aggrastat than you should</strong></p><p>Your dose of Aggrastat is carefully monitored and checked by your doctor and pharmacist.</p><p>The most frequently reported symptom of overdose is bleeding. If you notice bleeding, you should notify your healthcare professional immediately.</p><p>&nbsp;</p><p><strong>If you forget to use Aggrastat</strong></p><p>Your doctor will decide when to administer the dose.</p><p>&nbsp;</p><p><strong>If you stop using Aggrasta</strong>t</p><p>Your doctor will decide when treatment should be stopped. However, if you wish to stop your treatment earlier, you should discuss other options with your doctor.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>The most common side effect of treatment with Aggrastat is bleeding which could occur anywhere in the body. This can become serious and may, rarely, be fatal.</p><p>If side effects occur, they may need medical attention. While using Aggrastat, if you develop any of the following symptoms, you should contact your doctor immediately:</p><p>- signs of bleeding in the skull such as pain in the head, sensory impairments (visual or hearing),</p><p>&nbsp; &nbsp;difficulties in speech, numbness or problems with movement or balance</p><p>- signs of internal bleeding such as coughing up blood or blood in your urine or stool</p><p>- signs of serious allergic reactions such as difficulties in breathing and dizziness</p><p>&nbsp;</p><p>Below is a list of side effects that have occurred in some people following treatment with</p><p>Aggrastat. The side effects are listed in decreasing order of frequency.</p><p>&nbsp;</p><p><strong>Very common (may affect more than 1 in 10 people):</strong></p><p>&bull; Bleeding after surgery</p><p>&bull; Bleeding under the skin at the site of an injection, or into a muscle, causing swelling</p><p>&bull; Small red bruises on the skin</p><p>&bull; Invisible blood in urine or stool</p><p>&bull; Feeling sick</p><p>&bull; Headache</p><p>&nbsp;</p><p><strong>Common (may affect up to 1 in 10 people):</strong></p><p>&bull; Blood in urine</p><p>&bull; Coughing up of blood</p><p>&bull; Nose bleeds</p><p>&bull; Bleeding in the gums and mouth</p><p>&bull; Bleeding from vessel puncture site</p><p>&bull; Reduction in red blood cells (reduced haematocrit and haemoglobin)</p><p>&bull; Decreases in platelet count below 90,000/mm<sup>3</sup></p><p>&bull; Fever</p><p>&nbsp;</p><p><strong>Uncommon (may affect up to 1 in 100 people):</strong></p><p>&bull; Bleeding in the stomach or intestines</p><p>&bull; Vomiting of blood</p><p>&bull; Decreases in platelet count below 50,000/mm<sup>3</sup></p><p>&nbsp;</p><p><strong>Not known (frequency cannot be estimated from the available data):</strong></p><p>&bull; Bleeding in the skull</p><p>&bull; Haematoma in the spinal region</p><p>&bull; Bleeding in the abdomen of the internal organs</p><p>&bull; Accumulation of blood around the heart</p><p>&bull; Bleeding in the lung</p><p>&bull; Acute and/or severe decreases in platelet counts below 20,000/mm<sup>3</sup></p><p>&bull; Severe allergic reactions with tightness of chest, hives or nettle rash, including reactions that cause&nbsp;</p><p>&nbsp; &nbsp;difficulty in breathing and dizziness</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side</p><p>effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Keep this medicine out of the reach and sight of children.</strong></p><p>Do not store above 30&deg;C.</p><p>Your physician and pharmacist will know how to store and dispose of this medicine.</p><p>Do not use this medicine after the expiry date which is stated on the label and outer carton after EXP.</p><p>The expiry date refers to the last day of that month.</p><p>Do not freeze. Keep container in outer carton to protect from light.</p><p>Do not use this medicine if you notice there are visible particles or discolouration of the solution before use.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is tirofiban hydrochloride monohydrate.</p><p>1 ml of Aggrastat contains 281 micrograms of tirofiban hydrochloride monohydrate which is equivalent to 250 micrograms tirofiban.</p><p>The other ingredients are Sodium chloride, sodium citrate dihydrate, citric acid anhydrous, water for injection, hydrochloric acid and/or sodium hydroxide (for pH adjustment).</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Aggrastat is a clear, colourless concentrated solution available in a 50 ml Type I glass vial.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;</p><p>Marketing Authorization Holder And Final Batch Releaser :</p><p><strong>ALGORITHM S.A.L.</strong> Zouk Mosbeh, Lebanon</p><p>&nbsp;</p><p>Manufacturer:</p><p>Siegfried Hameln GmbH, Langes Feld 13, 31789 Hameln, Germany</p><p>&nbsp;</p><p><sup>&reg;</sup> Registered Trademark of Cardiome International AG.</p><p>All rights reserved.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Rev. 06/2018
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يُستعمل أغراستات لمساعدة وصول دفق الدم إلى قلبك وللمساعدة على منع ألم الصدر والنوبات القلبيّة. يعمل هذا الدواء عبر منع الصفيحات التي هي خلايا موجودة في دمك، من تشكيل جلطات دمويّة.</p><p dir="RTL">يمكن أيضًا استعمال هذا الدواء لدى المرضى الذين تكون أوعية القلب لديهم موسّعة بواسطة بالون (التدخّل التاجي عن طريق الجلد PCI). إنّه إجراء يتمّ لتحسين تدفق الدم إلى القلب مع إمكانيّة زرع أنبوب صغير (دعامة).</p><p dir="RTL">يُستعمل أغراستات مع&nbsp; الأسبرين والهيبارين غير المجزّأ.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستعمل أغراستات</strong></p><p dir="RTL">&bull; إذا كنت تعاني من حساسيّة (فرط حساسيّة) ضدّ التيروفيبان أو ضدّ أيّ مركّب من مركّبات أغراستات الأخرى. (راجع فقرة 6 ماذا يحتوي أغراستات).</p><p dir="RTL">&bull; إذا كنت تعاني من نزيف داخليّ أو أصبت سابقًا بنزيف داخليّ في خلال الأيّام الثلاثين الأخيرة.</p><p dir="RTL">&bull; إذا أصبت سابقًا بنزيف في الدماغ أو بورم في الدماغ أو كان لديك أوعية دمويّة غير طبيعيّة في الدماغ.</p><p dir="RTL">&bull; إذا كنت تعاني من ارتفاع ضغط الدم الحاد غير المتحكّم به (ارتفاع ضغط الدم الخبيث).</p><p dir="RTL">&bull; إذا كان عدد صفيحات الدم لديك منخفضًا (قلّة الصفيحات) أو كنت تعاني من مشاكل في تخثّر الدم.</p><p dir="RTL">&bull; إذا أصبت سابقًا بقلّة الصفيحات بعد تلقّي علاج بأغراستات أو بأيّ دواء من المجموعة ذاتها.</p><p dir="RTL">&bull; إذا أصبت بسكتة دماغيّة في خلال الأيّام الثلاثين الأخيرة أو إذا أصبت سابقًا بسكتة دماغيّة مع نزيف.</p><p dir="RTL">&bull; إذا أصبت بجروح خطيرة أو خضعت لجراحة كبيرة في خلال الأسابيع الستة الأخيرة.</p><p dir="RTL">&bull; إذا كنت تعاني من مرض حاد في الكبد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سوف يراجع طبيبك تاريخك الطبّي ليرى ما إذا كنت معرّضًا لازدياد خطر الإصابة بأيّ آثار جانبيّة ترتبط بتلقّي هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المحاذير والإحتياطات</strong></p><p dir="RTL">أعلم طبيبك قبل إستخدام أغراستات، إذا كان لديك حاليًا أو في السابق:</p><p dir="RTL">&bull; أيّ مشاكل طبيّة</p><p dir="RTL">&bull; أيّ حساسيّات</p><p dir="RTL">&bull; إنعاش قلبي رئوي، خزعة، أو إجراء تفتيت لحصى الكلى في خلال الأسبوعين الأخيرين</p><p dir="RTL">&bull; إذا أصبت بجروح خطيرة أو خضعت لجراحة كبيرة في خلال الأشهر الثلاثة الأخيرة</p><p dir="RTL">&bull; قرحة في المعدة أو الأمعاء (معي الإثنا عشر) في خلال الأشهر الثلاثة الأخيرة</p><p dir="RTL">&bull; اضطراب نزيف حديث (في غضون سنة واحدة) مثل نزيف في المعدة أو الأمعاء أو دم في البول أو البراز</p><p dir="RTL">&bull; إجراء حديث في العمود الفقري</p><p dir="RTL">&bull; سوابق أو عوارض انشطار الأبهر (تسلّخ الأبهر)</p><p dir="RTL">&bull; ارتفاع غير متحكّم به لضغط الدم (فرط ضغط الدم)</p><p dir="RTL">&bull; التهاب في البطانة حول قلبك (التهاب التأمور)</p><p dir="RTL">&bull; التهاب الأوعية الدمويّة (التهاب وعائي)</p><p dir="RTL">&bull; مشاكل في الأوعية الدمويّة في الجزء الخلفي من عينك (شبكيّة العين)</p><p dir="RTL">&bull; علاج بأدوية تساعد على منع أو حلّ جلطات الدم</p><p dir="RTL">&bull; مشاكل في الكلى</p><p dir="RTL">&bull; خط وريدي خاص تمّ إدخاله تحت عظم الترقوة في خلال الـ24 ساعة الأخيرة</p><p dir="RTL">&bull; فشل القلب</p><p dir="RTL">&bull; انخفاض كبير في ضغط الدم بسبب فشل القلب (صدمة قلبيّة)</p><p dir="RTL">&bull; اضطراب في الكبد</p><p dir="RTL">&bull; انخفاض تعداد الدم أو فقر دم</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أ</strong><strong>دوية أخرى وأغراستات</strong></p><p dir="RTL">بصورة عامة، يمكن استعمال أغراستات مع أدوية أخرى. الرجاء أن تُعلم طبيبك إذا كنت تأخذ حاليًا أو أخذت مؤخّرًا أيّ أدوية أخرى، بما فيها الأدوية التي يمكن الحصول عليها بدون وصفة طبيّة، لأنّ بعض الأدوية قد تؤثّر على مفعول بعضها البعض. من المهمّ بشكل خاص أن تُعلم طبيبك إذا كنت تأخذ أدوية أخرى يمكن أن تساعد على منع دمك من التخثّر مثل الوارفارين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>استعمال أغراستات مع الطعام والشراب</strong></p><p dir="RTL">لا يؤثّر الطعام والشراب على هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والإرضاع</strong></p><p dir="RTL">إذا كنتِ حاملاً أو مرضعة أو تعتقدين نفسكِ حاملا أو تنوين الحمل، استشيري طبيبك قبل استعمال هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستعمال الآلات</strong></p><p dir="RTL">بسبب حالتك المرضيّة، لن تتمكّن من قيادة السيّارات أو تشغيل آلات في خلال فترة استعمال أغراستات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي أغراستات على الصوديوم</strong></p><p dir="RTL">يحتوي هذا الدواء على 189 ملغرام تقريبًا من الصوديوم في قارورة من 50 مل. يجب أخذ هذا المحتوى بعين الاعتبار لدى المرضى الذين يتبعون نظامًا غذائيًا قليل الملح.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يجب أن يصف أغراستات طبيب مؤهّل لديه خبرة في إدارة النوبات القلبيّة.</p><p dir="RTL">لقد تلقّيت أو أنت على وشك أن تتلقّى أغراستات في وريد، سوف يقرّر طبيبك الجرعة المناسبة، حسب حالتك ووزنك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاستعمال لدى الأطفال</strong></p><p dir="RTL">لا يُنصح باستعمال هذا الدواء لدى الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا استعملت كميّة أغراستات أكثر مما يجب</strong></p><p dir="RTL">يراقب طبيبك والصيدلي الخاص بك ويتحققان بدقة من جرعة أغراستات التي تأخذها.&nbsp;</p><p dir="RTL">إنّ عارض فرط الجرعة الأكثر شيوعًا الذي أفيد عنه هو النزيف. فإذا لاحظت نزيفا، يجب أن تُعلم أخصّائي الرعاية الصحيّة الذي يتابعك على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا نسيت استعمال أغراستات</strong></p><p dir="RTL">سوف يقرر طبيبك موعد إعطاء الجرعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>توقفت</strong><strong> </strong><strong>عن</strong><strong> </strong><strong>استعمال</strong><strong> </strong><strong>أغراستات</strong></p><p dir="RTL">سوف يقرّر طبيبك متى يجب إيقاف العلاج. ولكن إذا رغبت في إيقاف علاجك في وقت أبكر، يجب أن تناقش خيارات أخرى مع طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان لديك أسئلة أخرى حول استعمال هذا الدواء، اطرحها على طبيبك أو على الصيدليّ الخاص بك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل الأدوية كلّها، يمكن أن يسبّب أغراستات آثارًا جانبيّة لا تُصيب المرضى كلّهم.</p><p dir="RTL">الأثر الجانبي الأكثر شيوعًا للعلاج بأغراستات هو النزيف الذي يمكن أن يحصل في أيّ مكان في الجسم. ويمكن أن يصبح النزيف خطيرًا ونادرًا ما يؤدي إلى الوفاة.</p><p dir="RTL">في حال حصول آثار جانبيّة، فقد تحتاج إلى عناية طبيّة. في خلال فترة استعمال أغراستات، إذا أصبت بأيّ من العوارض التالية، يجب أن تتصل بطبيبك على الفور:</p><p dir="RTL">- إشارات نزيف في الجمجمة مثل الصداع أو الاعتلالات الحسيّة (البصريّة أو السمعيّة) أو صعوبة الكلام أو الخدر أو مشاكل في الحركة أو التوازن</p><p dir="RTL">- إشارات نزيف داخلي مثل سعال الدم أو وجود دم في البول أو البراز</p><p dir="RTL">- إشارات ارتكاسات تحسسيّة خطيرة مثل صعوبة التنفّس والدوار</p><p dir="RTL">&nbsp;</p><p dir="RTL">ترد أدناه قائمة بالآثار الجانبيّة التي حصلت لدى بعض الأشخاص بعد العلاج بأغراستات.</p><p dir="RTL">يتم سرد الآثار الجانبية بحسب تناقص عدد مرّات حصولها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الشائعة جدًا (قد تصيب أكثر من مستعمل واحد من أصل 10):</strong></p><p dir="RTL">&bull; نزيف بعد الجراحة</p><p dir="RTL">&bull; نزيف تحت الجلد في موقع الحقن أو في عضل، يسبّب تورّمًا</p><p dir="RTL">&bull; كدمات حمراء صغيرة على الجلد</p><p dir="RTL">&bull; دم غير مرئي في البول أو البراز</p><p dir="RTL">&bull; غثيان</p><p dir="RTL">&bull; صداع</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الشائعة (قد تصيب مستعملاً واحدًا من أصل 10):</strong></p><p dir="RTL">&bull; دم في البول</p><p dir="RTL">&bull; سعال الدم</p><p dir="RTL">&bull; نزيف من الأنف</p><p dir="RTL">&bull; نزيف في اللثة والفم</p><p dir="RTL">&bull; نزيف من موقع ثقب الوعاء الدموي</p><p dir="RTL">&bull; انخفاض عدد خلايا الدم الحمراء (انخفاض الهيماتوكريت والهيموغلوبين)</p><p dir="RTL">&bull; انخفاض في عدد الصفيحات إلى ما دون 90000/مم<sup>3</sup></p><p dir="RTL">&bull; حمى</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير الشائعة (قد تصيب مستعملاً واحدًا من أصل 100):</strong></p><p dir="RTL">&bull; نزيف في المعدة أو الأمعاء</p><p dir="RTL">&bull; تقيّؤ دم</p><p dir="RTL">&bull; انخفاض في عدد الصفيحات إلى ما دون 50000/مم<sup>3</sup></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير المعروفة معدّل الحصول (لا يمكن تقديرها استنادًا إلى البيانات المتاحة):</strong></p><p dir="RTL">&bull; نزيف في الجمجمة</p><p dir="RTL">&bull; ورم دموي في منطقة العمود الفقري</p><p dir="RTL">&bull; نزيف في داخل الأعضاء الداخليّة</p><p dir="RTL">&bull; تراكم الدم حول القلب</p><p dir="RTL">&bull; نزيف في الرئة</p><p dir="RTL">&bull; انخفاضات حادة و/أو شديدة في عدد الصفيحات ما دون 20000/مم<sup>3</sup></p><p dir="RTL">&bull; ارتكاسات تحسسيّة حادة مع ضيق في الصدر أو شرى أو طفح القرّاص بما في ذلك ارتكاسات تسبّب صعوبة في التنفّس ودوارًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبيّة</strong></p><p dir="RTL">إذا أصبت بأحد االتأثيرات الجانبيّة، الرجاء إعلام الطبيب أوالصيدلي أو الممّرضة. وهذا يشمل اي آثار جانبيّة لم يتمّ ذكرها في هذه النشرة. عبر الإبلاغ عن الآثار الجانبيّة، يمكنك المساعدة في توفير المزيد من المعلومات حول سلامة هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>إحفظ الدواء بعيدًا عن متناول الأطفال ونظرهم.</strong></p><p dir="RTL">يحفظ في درجات حرارة لا تتعدّى 30 درجة مئوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يعرف طبيبك والصيدلي الخاص بك كيفيّة حفظ هذا الدواء والتخلّص منه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستعمل أغراستات بعد انقضاء تاريخ الصلاحيّة المذكور على اللصاقة وعلبة الكرتون الخارجيّة. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من الشهر المذكور.</p><p dir="RTL">لا تقم بتجميده. احفظ الحاوية في داخل علبة الكرتون الخارجيّة لحمايتها من الضوء.</p><p dir="RTL">لا تستعمل هذا الدّواء إذا كان يحتوي على جُسيمات مرئيّة أو في حال كان لون المحلول منحلاً قبل الاستعمال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلص من الأدوية في مياه الصرف الصحّي أو في النفايات المنزليّة. إسأل الصيدلي حول كيفيّة التخلّص من الأدوية التي لم تعد تحتاج إليها، فمن شأن هذه الإجراءات حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفاعلة هي هيدروكلورايد التيروفيبان الأحادي الهيدرات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي المليلتر الواحد على 281 ميكروغرام من هيدروكلورايد التيروفيبان الأحادي الهيدرات ما يعادل 250 ميكروغرام من التيروفيبان.</p><p dir="RTL">المركّبات الأخرى هي: كلورايد الصوديوم، سيترات الصوديوم الثنائي الهيدرات، حامض الستريك اللامائي، ماء للحقن، حامض الهيدروكلوريك و/أو هيدروكسيد الصوديوم (لضبط الرقم الهيدروجيني).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ب.كيف هو شكل أغراستات ومحتويات العلبة</strong></p><p dir="RTL">أغراستات هو محلول صافٍ عديم اللون ومركّز يأتي في قارورة زجاجيّة من النوع 1 سعة 50 مل.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مالك رخصة التسويق والمصنع المسؤول عن تحرير الصنف:</p><p dir="RTL"><strong>ألغوريتم ش.م.ل.</strong> ذوق مصبح، لبنان.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الشركة المصنّعة :</p><p dir="RTL">سيغفريد هاملن ش.م.م. لانغس فيلد 13، 31789 هاملن، المانيا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><sup>م </sup>علامة تجارية مسجلة لشركة كارديوم الدوليّة ش.م.</p><p dir="RTL">كافة الحقوق محفوظة.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            06/2018
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                AGGRASTAT®* concentrate solution for I.V. infusion equivalent to 0.25 mg/mL Tirofiban base. 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                1 ml of concentrate for solution for infusion contains 281 micrograms of tirofiban hydrochloride monohydrate which is equivalent to 250 micrograms tirofiban. 
 
For the full list of excipients, see section 6.1. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Aggrastat Concentrate: concentrate for solution for infusion (50 ml vial). A clear, colourless concentrated solution. 
 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Aggrastat is indicated for the prevention of early myocardial infarction in adult patients presenting with acute coronary syndromes without ST elevation (NSTE-ACS) with the last episode of chest pain occurring within 12 hours and with ECG changes and/or elevated cardiac enzymes.</p><p>Patients most likely to benefit from Aggrastat treatment are those at high risk of developing myocardial infarction within the first 3-4 days after onset of acute angina symptoms including for instance those that are likely to undergo an early percutaneous coronary intervention (PCI). Aggrastat is also indicated for the reduction of major cardiovascular events in patients with acute myocardial infarction (STEMI) intended for primary PCI (see sections 4.2 and 5.1).</p><p><!--[if gte vml 1]><o:wrapblock><v:group id="Group_x0020_26343" o:spid="_x0000_s1028"
  style='position:absolute;left:0;text-align:left;margin-left:14.15pt;
  margin-top:297.65pt;width:5.65pt;height:.3pt;z-index:251658240;
  mso-position-horizontal-relative:page;mso-position-vertical-relative:page'
  coordsize="71755,3810" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
  <v:shape id="Shape_x0020_7" o:spid="_x0000_s1029" style='position:absolute;
   width:71755;height:3810;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="71755,3810" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,3810r71755,l71755,,,,,3810xe" filled="f">
   <v:stroke miterlimit="83231f" joinstyle="miter"/>
   <v:path arrowok="t" textboxrect="0,0,71755,3810"/>
  </v:shape><w:wrap type="topAndBottom" anchorx="page" anchory="page"/>
 </v:group><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="10" height="2" src="file:///C:/Users/ph-a-/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--><br /><!--[if gte vml 1]><v:group id="Group_x0020_26344" o:spid="_x0000_s1026"
 style='position:absolute;left:0;text-align:left;margin-left:19.85pt;
 margin-top:422.35pt;width:8.5pt;height:.3pt;z-index:251659264;
 mso-position-horizontal-relative:page;mso-position-vertical-relative:page'
 coordsize="107950,3810" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:shape id="Shape_x0020_8" o:spid="_x0000_s1027" style='position:absolute;
  width:107950;height:3810;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="107950,3810" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,3810r107950,l107950,,,,,3810xe" filled="f">
  <v:stroke miterlimit="83231f" joinstyle="miter"/>
  <v:path arrowok="t" textboxrect="0,0,107950,3810"/>
 </v:shape><w:wrap type="square" anchorx="page" anchory="page"/>
</v:group><![endif]--><img width="14" height="2" src="file:///C:/Users/ph-a-/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" />&nbsp;</p><p>&nbsp;</p><p>Aggrastat is intended for use with acetylsalicylic acid (ASA) and unfractionated heparin.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This product is for hospital use only, by specialist physicians experienced in the management of acute coronary syndromes.</p><p>&nbsp;</p><p>Aggrastat Concentrate must be diluted before use.</p><p>&nbsp;</p><p>Aggrastat should be administered with unfractionated heparin and oral antiplatelet therapy, including ASA.</p><p>&nbsp;</p><p><u>Posology</u></p><p>In patients who are managed with an early invasive strategy for NSTE-ACS but not planned to undergo angiography for at least 4 hours and up to 48 hours after diagnosis, Aggrastat is given intravenously at an initial infusion rate of 0.4 microgram/kg/min for 30 minutes. At the end of the initial infusion, Aggrastat should be continued at a maintenance infusion rate of 0.1 microgram/kg/min. Aggrastat should be given with unfractionated heparin (usually an intravenous bolus of 50-60 units [U]/kg simultaneously with the start of Aggrastat therapy, then approximately 1,000 U per hour, titrated on the basis of the activated thromboplastin time [APTT], which should be about twice the normal value) and oral antiplatelet therapy, including but not limited to ASA (see section 5.1), unless contraindicated.</p><p>&nbsp;</p><p>In NSTE-ACS patients planned to undergo PCI within the first 4 hours of diagnosis or in patients with acute myocardial infarction intended for primary PCI, Aggrastat should be administered utilizing an initial bolus of 25 microgram/kg given over a 3 minute period, followed by a continuous infusion at a rate of 0.15 microgram/kg/min for 12-24, and up to 48 hours. Aggrastat should be administered with unfractionated heparin (dosage as above) and oral antiplatelet therapy, including but not limited to ASA (see section 5.1), unless contra-indicated.</p><p><s>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </s>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><em>&nbsp;</em></p><p><em>Elderly </em></p><p>No dosage adjustment is necessary for the elderly (see section 4.4).</p><p><em>&nbsp;</em></p><p>Patients with severe kidney failure</p><p>In severe kidney failure (creatinine clearance &lt;30 ml/min) the dosage of Aggrastat should be reduced by 50% (see sections 4.4 and 5.2).</p><p>&nbsp;</p><p>Paediatric population</p><p>The safety and efficacy of Aggrastat in children aged &lt; 18 years have not been established. No data are available.</p><p>&nbsp;</p><p>Table 1 is provided as a guide to dosage adjustment by weight.</p><p><strong>Aggrastat Concentrate must be diluted to the same strength as Aggrastat Solution, as noted under <em>Instructions for Use</em>. </strong></p><p><strong>&nbsp;</strong></p><p><strong>Table 1: Dosing Table </strong></p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:683px"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>Patient</p><p>Weight (kg)</p></td><td colspan="2" style="vertical-align:top"><p><strong>0.4 microgram/kg/min </strong></p><p><strong>Loading Dose Regimen Most Patients </strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>0.4 microgram/kg/min </strong></p><p><strong>Loading Dose Regimen </strong></p><p><strong>Severe Kidney Failure </strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>25 microgram/kg&nbsp; </strong></p><p><strong>Dose Bolus Regimen&nbsp; Most Patients </strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>25 microgram/kg&nbsp; </strong></p><p><strong>Dose Bolus Regimen&nbsp; </strong></p><p><strong>Severe Kidney Failure </strong></p></td></tr><tr><td style="vertical-align:top"><p>30 min</p><p>Loading</p><p>Infusion</p><p>Rate</p><p>(ml/hr)</p></td><td style="vertical-align:top"><p>Maintenance</p><p>Infusion</p><p>Rate</p><p>(ml/hr)</p></td><td style="vertical-align:top"><p>30 min</p><p>Loading</p><p>Infusion</p><p>Rate</p><p>(ml/hr)</p></td><td style="vertical-align:top"><p>Maintenance</p><p>Infusion</p><p>Rate</p><p>(ml/hr)</p></td><td style="vertical-align:top"><p>Bolus</p><p>(ml)</p></td><td style="vertical-align:top"><p>Maintenance Infusion&nbsp;</p><p>Rate&nbsp;</p><p>(ml/hr)</p></td><td style="vertical-align:top"><p>Bolus</p><p>(ml)</p></td><td style="vertical-align:top"><p>Maintenance Infusion&nbsp;</p><p>Rate&nbsp;</p><p>(ml/hr)</p></td></tr><tr><td style="vertical-align:top"><p>30-37</p></td><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>3</p></td></tr><tr><td style="vertical-align:top"><p>38-45</p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>21</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>4</p></td></tr><tr><td style="vertical-align:top"><p>46-54</p></td><td style="vertical-align:top"><p>24</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>5</p></td></tr><tr><td style="vertical-align:top"><p>55-62</p></td><td style="vertical-align:top"><p>28</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>29</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>5</p></td></tr><tr><td style="vertical-align:top"><p>63-70</p></td><td style="vertical-align:top"><p>32</p></td><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>33</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>6</p></td></tr><tr><td style="vertical-align:top"><p>71-79</p></td><td style="vertical-align:top"><p>36</p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>38</p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>19</p></td><td style="vertical-align:top"><p>7</p></td></tr><tr><td style="vertical-align:top"><p>80-87</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>42</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>21</p></td><td style="vertical-align:top"><p>8</p></td></tr><tr><td style="vertical-align:top"><p>88-95</p></td><td style="vertical-align:top"><p>44</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>22</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>46</p></td><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>23</p></td><td style="vertical-align:top"><p>8</p></td></tr><tr><td style="vertical-align:top"><p>96-104</p></td><td style="vertical-align:top"><p>48</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>24</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>50</p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>9</p></td></tr><tr><td style="vertical-align:top"><p>105-112</p></td><td style="vertical-align:top"><p>52</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>26</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>54</p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>27</p></td><td style="vertical-align:top"><p>10</p></td></tr><tr><td style="vertical-align:top"><p>113-120</p></td><td style="vertical-align:top"><p>56</p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>28</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>58</p></td><td style="vertical-align:top"><p>21</p></td><td style="vertical-align:top"><p>29</p></td><td style="vertical-align:top"><p>10</p></td></tr><tr><td style="vertical-align:top"><p>121-128</p></td><td style="vertical-align:top"><p>60</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>30</p></td><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>62</p></td><td style="vertical-align:top"><p>22</p></td><td style="vertical-align:top"><p>31</p></td><td style="vertical-align:top"><p>11</p></td></tr><tr><td style="vertical-align:top"><p>129-137</p></td><td style="vertical-align:top"><p>64</p></td><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>32</p></td><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>67</p></td><td style="vertical-align:top"><p>24</p></td><td style="vertical-align:top"><p>33</p></td><td style="vertical-align:top"><p>12</p></td></tr><tr><td style="vertical-align:top"><p>138-145</p></td><td style="vertical-align:top"><p>68</p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>34</p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>71</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>35</p></td><td style="vertical-align:top"><p>13</p></td></tr><tr><td style="vertical-align:top"><p>146-153</p></td><td style="vertical-align:top"><p>72</p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>36</p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>75</p></td><td style="vertical-align:top"><p>27</p></td><td style="vertical-align:top"><p>37</p></td><td style="vertical-align:top"><p>13</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p>Start and duration of therapy with Aggrastat</p><p>In patients who are managed with an early invasive strategy for NSTE-ACS but not planned to undergo angiography for at least 4 hours and up to 48 hours after diagnosis, Aggrastat 0.4 microgram/kg/min loading dose regimen should be initiated upon diagnosis. The recommended duration of the maintenance infusion should be at least 48 hours. Infusion of Aggrastat and unfractionated heparin may be continued during coronary angiography and should be maintained for at least 12 hours and not more than 24 hours after angioplasty/atherectomy. Once a patient is clinically stable and no coronary intervention procedure is planned by the treating physician, the infusion should be discontinued. The entire duration of treatment should not exceed 108 hours.</p><p>&nbsp;</p><p>If the patient diagnosed with NSTE-ACS and managed with an invasive strategy undergoes angiography within 4 hours after the diagnosis, the Aggrastat 25 microgram/kg dose bolus regimen should be initiated at the start of PCI with the infusion continued for 12-24 hours and up to 48 hours.&nbsp;</p><p>In patients with acute myocardial infarction intended for primary PCI, the 25 microgram/kg dose bolus regimen should be initiated as soon as possible after diagnosis.</p><p>&nbsp;</p><p>Concurrent therapy (unfractionated heparin, oral antiplatelet therapy, including ASA)&nbsp;</p><p>Treatment with unfractionated heparin is initiated with an i.v. bolus of 50-60 U/kg and then continued with a maintenance infusion of 1,000 U per hour. The heparin dosage is titrated to maintain an APTT of approximately twice the normal value.</p><p>&nbsp;</p><p>Unless contra-indicated, all patients should receive oral antiplatelet agents, including but not limited to ASA, before the start of Aggrastat (see section 5.1). This medication should be continued at least for the duration of the infusion of Aggrastat.</p><p>Most studies investigating the administration of Aggrastat as an adjunct to PCI have used ASA in combination with clopidogrel as oral antiplatelet therapy. The efficacy of the combination of Aggrastat with either prasugrel or ticagrelor has not been established in randomised controlled trials.</p><p>&nbsp;</p><p>If angioplasty (PCI) is required, heparin should be stopped after PCI, and the sheaths should be withdrawn once coagulation has returned to normal, e.g. when the activated clotting time (ACT) is less than 180 seconds (usually 2-6 hours after discontinuation of heparin).</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>&nbsp;</p><p><strong><em>Instructions for use</em></strong></p><p><em>Aggrastat Concentrate must be diluted before use: </em></p><p>&nbsp;</p><p>1.&nbsp;&nbsp; Draw 50 ml from a 250 ml container of sterile 0.9% saline or 5% glucose in water and replace with 50 ml Aggrastat (from one 50 ml puncture vial) to make up a concentration of 50 microgram/ml.&nbsp; Mix well before use.</p><p>&nbsp;</p><p>2.&nbsp;&nbsp; Use according to the dosage table above.</p><p>&nbsp;</p><p>Where the solution and container permit, parenteral drugs should be inspected for visible particles or discoloration before use.&nbsp;</p><p>&nbsp;</p><p>Aggrastat should only be given intravenously and may be administered with unfractionated heparin through the same infusion tube.</p><p>&nbsp;</p><p>It is recommended that Aggrastat be administered with a calibrated infusion set using sterile equipment.</p><p>Care should be taken to ensure that no prolongation of the infusion of the initial dose occurs and that miscalculation of the infusion rates for the maintenance dose on the basis of the patient&rsquo;s weight is avoided.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Aggrastat is contra-indicated in patients who are hypersensitive to the active substance or to any of the excipients of the preparation listed in section 6.1 or who developed thrombocytopenia during earlier use of a GP IIb/IIIa receptor antagonist. 
Since inhibition of platelet aggregation increases the bleeding risk, Aggrastat is contra-indicated in patients with: 
 
•	History of stroke within 30 days or any history of haemorrhagic stroke. 
•	Known history of intracranial disease (e.g. neoplasm, arteriovenous malformation, aneurysm). 
•	Active or recent (within the previous 30 days of treatment) clinically relevant bleeding (e.g. gastro-intestinal bleeding). 
•	Malignant hypertension. 
•	Relevant trauma or major surgical intervention within the past six weeks. 
•	Thrombocytopenia (platelet count <100,000/mm3), disorders of platelet function. 
•	Clotting disturbances (e.g. prothrombin time >1.3 times normal or INR [International Normalised Ratio] >1.5). 
•	Severe liver failure. 
 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The administration of Aggrastat alone without unfractionated heparin is not recommended.&nbsp;&nbsp;</p><p>&nbsp;</p><p>There is limited experience with concomitant administration of Aggrastat with enoxaparin (see sections 5.1 and 5.2). The concomitant administration of Aggrastat with enoxaparin is associated with a higher frequency of cutaneous and oral bleeding events, but not in TIMI bleeds<sup><sup>[1]</sup></sup>, when compared with the concomitant administration of Aggrastat and unfractionated heparin.&nbsp; An increased risk of serious bleeding events associated with the concomitant administration of Aggrastat and enoxaparin cannot be excluded, particularly in patients given additional unfractionated heparin in conjunction with angiography and/or PCI.&nbsp; The efficacy of Aggrastat in combination with enoxaparin has not been established.&nbsp; The safety and efficacy of Aggrastat with other low molecular weight heparins has not been investigated.</p><p>&nbsp;</p><p>There is insufficient experience with the use of tirofiban hydrochloride in the following diseases and conditions, however, an increased risk of bleeding is suspected. Therefore, tirofiban hydrochloride is not recommended in:</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Traumatic or protracted cardiopulmonary resuscitation, organ biopsy or lithotripsy within the past two weeks</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe trauma or major surgery &gt;6 weeks but &lt;3 months previously</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Active peptic ulcer within the past three months</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Uncontrolled hypertension (&gt;180/110 mm Hg)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acute pericarditis</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Active or a known history of vasculitis</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Suspected aortic dissection</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Haemorrhagic retinopathy</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Occult blood in the stool or haematuria</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Thrombolytic therapy (see section 4.5).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Concurrent use of drugs that increase the risk of bleeding to a relevant degree (see section 4.5).</p><p>&nbsp;</p><p>There is no therapeutic experience with tirofiban hydrochloride in patients for whom thrombolytic therapy is indicated. Consequently, the use of tirofiban hydrochloride is not recommended in combination with thrombolytic therapy.</p><p>&nbsp;</p><p>Aggrastat infusion should be stopped immediately if circumstances arise that necessitate thrombolytic therapy</p><p>[1] TIMI major bleeds are defined as a haemoglobin drop of &gt; 50 g/l with or without an identified site, intracranial haemorrhage, or cardiac tamponade.&nbsp; TIMI minor bleeds are defined as a haemoglobin drop of &gt; 30 g/l but  50 g/l with bleeding from a known site or spontaneous gross haematuria, haematemesis, or haemoptysis.&nbsp; TIMI &ldquo;loss no site&rdquo; is defined as a haemoglobin drop &gt; 40 g/l but &lt; 50 g/l without an identified bleeding site.</p><p>(including acute occlusion during PCI) or if the patient must undergo an emergency coronary artery bypass graft (CABG) operation or requires an intra-aortic balloon pump.</p><p>&nbsp;</p><p>Paediatric population</p><p>There is no therapeutic experience with Aggrastat in children, thus, the use of Aggrastat is not recommended in these patients.</p><p>&nbsp;</p><p>Other precautionary notes and measures<strong> </strong></p><p>There are insufficient data regarding the re-administration of Aggrastat.</p><p>&nbsp;</p><p>Patients should be carefully monitored for bleeding during treatment with Aggrastat. If treatment of haemorrhage is necessary, discontinuation of Aggrastat should be considered (see section 4.9). In cases of major or uncontrollable bleeding, tirofiban hydrochloride should be discontinued immediately.</p><p>&nbsp;</p><p>Aggrastat should be used with special caution in the following conditions and patient groups:</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Recent clinically relevant bleeding (less than one year)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Puncture of a non-compressible vessel within 24 hours before administration of Aggrastat</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Recent epidural procedure (including lumbar puncture and spinal anaesthesia)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe acute or chronic heart failure  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cardiogenic shock</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mild to moderate liver insufficiency</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Platelet count &lt;150,000/mm<sup>3</sup>, known history of coagulopathy or platelet function disturbance or thrombocytopenia</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Haemoglobin concentration less than 11 g/dl or haematocrit &lt;34%.</p><p>&nbsp;</p><p>Special caution should be used during concurrent administration of ticlopidine, clopidogrel, adenosine, dipyridamole, sulfinpyrazone, and prostacyclin.</p><p><em>&nbsp;</em></p><p>Efficacy with regard to dose</p><p>The administration of a 10 microgram/kg bolus regimen of tirofiban failed to show noninferiority in clinically relevant endpoints at 30 days compared to abciximab (see section 5.1).</p><p>&nbsp;</p><p>Elderly patients, female patients, and patients with low body weight</p><p>Elderly and/or female patients had a higher incidence of bleeding complications than younger or male patients, respectively.&nbsp; Patients with a low body weight had a higher incidence of bleeding than patients with a higher body weight. For these reasons Aggrastat should be used with caution in these patients and the heparin effect should be carefully monitored.</p><p>&nbsp;</p><p>Impaired renal function</p><p>There is evidence from clinical studies that the risk of bleeding increases with decreasing creatinine clearance and hence also reduced plasma clearance of tirofiban. Patients with decreased renal function (creatinine clearance &lt;60ml/min) should therefore be carefully monitored for bleeding during treatment with Aggrastat and the heparin effect should be carefully monitored.&nbsp; In severe kidney failure the Aggrastat dosage should be reduced (see section 4.2).</p><p>&nbsp;</p><p>&nbsp;</p><p>Femoral artery line</p><p>During treatment with Aggrastat there is a significant increase in bleeding rates, especially in the femoral artery area, where the catheter sheath is introduced. Care should be taken to ensure that only the anterior wall of the femoral artery is punctured. Arterial sheaths may be removed when coagulation has returned to normal, e.g. when activated clotting time (ACT) is less than 180 seconds, (usually 2&ndash;6 hours after discontinuation of heparin).</p><p>&nbsp;</p><p>After removal of the introducer sheath, careful haemostasis should be ensured under close observation.</p><p><em>&nbsp;</em></p><p>General nursing care</p><p>The number of vascular punctures, and intramuscular injections should be minimised during the treatment with Aggrastat. I.V. access should only be obtained at compressible sites of the body.&nbsp; All vascular puncture sites should be documented and closely monitored. The use of urinary catheters, nasotracheal intubation and nasogastric tubes should be critically considered.</p><p>&nbsp;</p><p>Monitoring of laboratory values</p><p>Platelet count, haemoglobin and haematocrit levels should be determined before treatment with Aggrastat as well as within 2-6 hours after start of therapy with Aggrastat and at least once daily thereafter while on therapy (or more often if there is evidence of a marked decrease).&nbsp; In patients who have previously received GPIIb/IIIa receptor antagonists (cross reactivity can occur), the platelet count should be monitored immediately e.g. within the first hour of administration after re-exposure (see section 4.8).&nbsp; If the platelet count falls below 90,000/mm<sup>3</sup>,<sup> </sup>further platelet counts should be carried out in order to rule out pseudothrombocytopenia.&nbsp; If thrombocytopenia is confirmed, Aggrastat and heparin should be discontinued. Patients should be monitored for bleeding and treated if necessary (see section 4.9).&nbsp;</p><p>&nbsp;</p><p>In addition, activated thromboplastin time (APTT) should be determined before treatment and the anticoagulant effects of heparin should be carefully monitored by repeated determinations of APTT and the dose should be adjusted accordingly (see section 4.2). Potentially life-threatening bleeding may occur especially when heparin is administered with other products affecting haemostasis, such as GPIIb/IIIa receptor antagonists.</p><p>&nbsp;</p><p>Sodium content</p><p>&nbsp;</p><p>Aggrastat concentrate for solution for infusion contains approximately 189 mg of sodium per 50 ml vial which should be taken into consideration by patients on a controlled sodium diet.</p><p>&nbsp;</p><p>&nbsp;</p><p>[1] TIMI major bleeds are defined as a haemoglobin drop of &gt; 50 g/l with or without an identified site, intracranial haemorrhage, or cardiac tamponade.&nbsp; TIMI minor bleeds are defined as a haemoglobin drop of &gt; 30 g/l but  50 g/l with bleeding from a known site or spontaneous gross haematuria, haematemesis, or haemoptysis.&nbsp; TIMI &ldquo;loss no site&rdquo; is defined as a haemoglobin drop &gt; 40 g/l but &lt; 50 g/l without an identified bleeding site.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The use of several platelet aggregation inhibitors increases the risk of bleeding, likewise their combination with heparin, warfarin and thrombolytics. Clinical and biological parameters of haemostasis should be regularly monitored.</p><p>&nbsp;</p><p>The concomitant administration of Aggrastat and ASA increases the inhibition of platelet aggregation to a greater extent than ASA alone, as measured by <em>ex vivo</em> APD-induced platelet aggregation test. The concomitant administration of Aggrastat and unfractionated heparin increases the prolongation of the bleeding time to a greater extent as compared to unfractionated heparin alone.</p><p>&nbsp;</p><p>With the concurrent use of Aggrastat, unfractionated heparin, ASA, and clopidogrel there was a comparable incidence of bleeding than when only unfractionated heparin, ASA, and clopidogrel were used together (see sections 4.4 and 4.8).</p><p>&nbsp;</p><p>Aggrastat prolonged bleeding time; however, the combined administration of Aggrastat and ticlopidine did not additionally affect bleeding time.</p><p>&nbsp;</p><p>Concomitant use of warfarin with Aggrastat plus heparin was associated with an increased risk of bleeding.</p><p>&nbsp;</p><p>Aggrastat is not recommended in thrombolytic therapy - concurrent or less than 48 hours before administration of tirofiban hydrochloride or concurrent use of drugs that increase the risk of bleeding to a relevant degree (e.g. oral anticoagulants, other parenteral GP IIb/IIIa inhibitors, dextran solutions). There is insufficient experience with the use of tirofiban hydrochloride in these conditions; however, an increased risk of bleeding is suspected.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy</p><p>There are no or limited amount of data from the use of tirofiban hydrochloride in pregnant women. Animal studies are insufficient with respect to reproductive toxicity (see section 5.3). Aggrastat is not recommended during pregnancy unless clearly necessary<strong><em>. </em></strong></p><p>&nbsp;</p><p>Breastfeeding</p><p>It is unknown whether tirofiban hydrochloride is excreted in human milk. Available pharmacodynamic/toxicological data in animals have shown excretion of tirofiban hydrochloride in milk (for details see section 5.3). A risk to the newborn cannot be excluded. A decision must be made whether to discontinue breastfeeding or to discontinue Aggrastat therapy, taking into account the benefit of breastfeeding for the child and the benefit of therapy for the woman.</p><p>Fertility</p><p>Fertility and reproductive performance were not affected in studies with male and female rats treated with different doses of tirofiban hydrochloride (see section 5.3).</p><p>However, animal studies are insufficient to draw conclusions with respect to reproductive toxicity in humans.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not relevant.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>a. Summary of safety profile</u></p><p>The most common adverse reaction reported during therapy with Aggrastat, when used concomitantly with heparin, aspirin and other oral anti-platelet agents, was bleeding, which usually involved mild mucocutaneous bleeding or mild catheterization-site bleeding.&nbsp;</p><p>Gastro-intestinal, retro-peritoneal, intracranial, haemorrhoidal and post-operative bleeding, epidural haematoma in the spinal region, haemopericardium and pulmonary (alveolar) haemorrhage have also been reported. Rates of TIMI major and intracranial bleeding in the pivotal Aggrastat studies were <u>&lt;</u>2.2% and &lt;0.1%, respectively. The most serious adverse reaction was fatal bleeding.</p><p>In the pivotal studies, administration of Aggrastat was associated with thrombocytopenia (platelet count &lt;90,000/mm<sup>3</sup>), occurring in 1.5% of patients treated with Aggrastat and heparin. The incidence of severe thrombocytopenia (platelet count &lt;50,000/mm<sup>3</sup>) was 0.3%. The most common non-bleeding adverse drug reactions associated with Aggrastat given concurrently with heparin were nausea (1.7%), fever (1.5%) and headache (1.1%).</p><p>&nbsp;</p><p><u>b. Tabulated summary of adverse reactions</u></p><p>Table 2 lists the adverse reactions based on experience from six double-blind controlled clinical studies (including 1953 patients receiving Aggrastat plus heparin) as well as adverse reactions reported from post-marketing experience. Within the organ system classes, adverse reactions are listed under headings of frequency using the following categories: very common (<u>&gt;</u> 1/10); common (<u>&gt;</u>1/100 to &lt;1/10); uncommon (<u>&gt;</u>1/1,000 to &lt;1/100); rare (<u>&gt;</u>1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000), not known (cannot be estimated from the available data). Because post-marketing events are derived from spontaneous reports from a population of uncertain size, it is not possible to determine their exact incidence. Therefore, the frequency of these adverse reactions is categorised as not known.</p><p>&nbsp;</p><p><strong>Table 2: Undesirable effects in clinical studies and from post-marketing experience. </strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:712px"><tbody><tr><td><p><strong>System Organ Class </strong></p></td><td><p><strong>Very common </strong></p></td><td><p><strong>Common </strong></p></td><td><p><strong>Uncommon </strong></p></td><td><p><strong>Not known </strong></p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Acute and/or severe</p><p>(&lt;20,000/mm3) decreases in platelet counts</p></td></tr><tr><td style="vertical-align:top"><p>Immune System</p><p>Disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Severe allergic reactions including anaphylactic reactions.&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Headache&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Intracranial bleeding, spinal epidural haematoma&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hemopericardium</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Haematoma&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Haemoptysis, epistaxis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pulmonary (alveolar) haemorrhage<strong> </strong></p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Nausea&nbsp;</p></td><td style="vertical-align:top"><p>Oral haemorrhage gingival haemorrhage&nbsp;</p></td><td style="vertical-align:top"><p>GI haemorrhage, haematemesis</p></td><td style="vertical-align:top"><p>Retroperitoneal bleeding</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Ecchymosis&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Haematuria</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Fever</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Injury, poisoning and procedural complications</p></td><td style="vertical-align:top"><p>Post-operative haemorrhage<sup>* </sup></p></td><td style="vertical-align:top"><p>Vessel puncture site haemorrhage</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>Occult blood in stool or urine&nbsp;</p></td><td style="vertical-align:top"><p>Decreases in haematocrit and haemoglobin, platelet counts &lt;90,000/mm<sup>3</sup></p></td><td style="vertical-align:top"><p>Platelet counts &lt;50,000/mm<sup>3</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>*Primarily related to catheterization sites. </strong></p><p>&nbsp;</p><p>&nbsp;</p><p><u>c. Description of selected adverse reactions</u></p><p>Bleeding &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p><p><em>&nbsp;</em></p><p>Both, with the Aggrastat 0.4 microgram/kg/min infusion regimen and the 25 microgram/kg dose bolus regimen, rates of major bleeding complications are low and not significantly increased.</p><p>&nbsp;</p><p>In the PRISM-PLUS study, using the Aggrastat 0.4 microgram/kg/min infusion regimen, the incidence of TIMI major bleeding was 1.4% for Aggrastat in combination with heparin and 0.8% for heparin alone. The incidence of TIMI minor bleeding was 10.5% for Aggrastat in combination with heparin and 8.0% for heparin alone. The percentage of patients who received a transfusion was 4.0% for Aggrastat in combination with heparin and 2.8% for heparin alone.</p><p>&nbsp;</p><p>With the Aggrastat 25 microgram/kg dose bolus regimen, data from the ADVANCE study suggest that the number of bleeding events is low and does not seem to be significantly increased compared to placebo. There were no TIMI major bleedings and no transfusions in either group. TIMI minor bleeding with the Aggrastat 25 microgram/kg dose bolus regimen was 4% as compared with 1% in the placebo arm p=0.19).</p><p>&nbsp;</p><p>In the On-TIME 2 study, there were no significant differences in the incidence of TIMI major bleeding (3.4% vs. 2.9% p =0.58) and TIMI minor bleeding (5.9% vs. 4.4%; p=0.206) between the Aggrastat 25 microgram/kg dose bolus regimen and the control arm.&nbsp;</p><p>&nbsp;</p><p>The rates of TIMI major (2.4% vs. 1.6%; p=0.44) or minor bleeding (4.8% vs. 6.2%; p=0.4) were also not significantly different between the Aggrastat 25 microgram/kg dose and the standard dose of abciximab, which were compared in the MULTISTRATEGY study.&nbsp;</p><p>&nbsp;</p><p>Based upon an assessment of haemorrhagic complications performed in the context of a meta-analysis (n=4076 ACS patients), the Aggrastat 25 microgram/kg dose bolus regimen does not significantly increase the rates of major bleeding, or thrombocytopenia, when compared to placebo. When considering the trials of the Aggrastat 25 microgram/kg bolus regimen compared with abciximab, individual study results do not demonstrate a significant difference in major bleeding between the two treatments<em>. </em>&nbsp;</p><p>&nbsp;</p><p>Thrombocytopenia</p><p>During Aggrastat therapy, acute decreases in platelet count or thrombocytopenia occurred more frequently than in the placebo group. These decreases were reversible upon discontinuation of Aggrastat. Acute and severe platelet (platelet counts &lt;20,000/mm<sup>3</sup>) decreases have been observed in patients with no prior history of thrombocytopenia upon re-administration of GPIIb/IIIa receptor antagonists and may be associated with chills, low-grade fever or bleeding complications.</p><p>&nbsp;</p><p>Analysis of the studies comparing the 25 microgram/kg dose bolus regimen against abciximab yielded a significantly lower rate of thrombocytopenia for Aggrastat (0.45% vs. 1.7%; OR=0.31; p=0.004).</p><p>&nbsp;</p><p>Allergic reactions</p><p>Severe allergic reactions (e.g., bronchospasm, urticaria) including anaphylactic reactions have occurred during initial treatment (also on the first day) and during readministration of Aggrastat. Some cases have been associated with severe thrombocytopenia (platelet counts &lt;10,000/mm<sup>3</sup>).</p><p>&nbsp;</p><p><strong>To report any side effect(s): </strong></p><p>Saudi Arabia: National Pharmacovigilance and Drug Safety Center (NPC)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; Call NPC at +966-11-2038222, Exts: 2317-2356-2340</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; Fax: +966-11-205-7662</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; Toll-free: 8002490000</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; Email: npc.drug@sfda.gov.sa</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; Website: www. sfda.gov.sa/npc</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Inadvertent overdose with tirofiban hydrochloride occurred in the clinical studies, up to 50 microgram/kg as a three minute bolus or 1.2 microgram/kg/min as an initial infusion. Overdose with up to 1.47 microgram/kg/min as a maintenance infusion rate has also occurred.</p><p>&nbsp;</p><p>a)&nbsp;&nbsp; Symptoms of overdose</p><p>The symptom of overdose most commonly reported was bleeding, usually mucosal bleeding and localised bleeding at the arterial puncture site for cardiac catheterisation but also single cases of intracranial haemorrhages and retroperitoneal bleedings (see sections 4.4 and 5.1).</p><p>&nbsp;</p><p>b)&nbsp;&nbsp; Measures</p><p>Overdose with tirofiban hydrochloride should be treated in accordance with the patient&rsquo;s condition and the attending physician&rsquo;s assessment. If treatment of haemorrhage is necessary, the Aggrastat infusion should be discontinued. Transfusions of blood and/or thrombocytes should also be considered. Aggrastat can be removed by haemodialysis.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Blood and blood forming organs &ndash; antithrombotic agents &ndash;antithrombotic agents &ndash; Platelet aggregation inhibitors excl. heparin</p><p>ATC-Code: B01A C17</p><p><em>&nbsp;</em></p><p><u>Mechanism of action</u>&nbsp;</p><p>Tirofiban hydrochloride (tirofiban) is a non-peptidal antagonist of the GP IIb/IIIa receptor, an important platelet surface receptor involved in platelet aggregation. Tirofiban prevents fibrinogen from binding to the GP IIb/IIIa receptor, thus blocking platelet aggregation.&nbsp;</p><p>Tirofiban leads to inhibition of platelet function, evidenced by its ability to inhibit ex vivo ADP-induced platelet aggregation and to prolong bleeding time (BT). Platelet function returns to baseline within eight hours after discontinuation.&nbsp;</p><p>The extent of this inhibition runs parallel to the tirofiban plasma concentration.&nbsp;</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>In the 0.4 microgram/kg/min infusion regimen of tirofiban, in the presence of unfractionated heparin and ASA, tirofiban produced a more than 70% (median 89%) inhibition of ex vivo ADP-induced platelet aggregation in 93% of the patients, and a prolongation of the bleeding time by a factor of 2.9 during infusion. Inhibition was achieved rapidly with the 30-minute loading infusion and was maintained over the duration of the infusion.</p><p>&nbsp;</p><p>The tirofiban 25 microgram/kg dose bolus regimen (followed by 18-24 hour maintenance infusion of 0.15 microgram/kg/min), in the presence of unfractionated heparin and oral antiplatelet therapy, produced an average ADP-induced inhibition of maximal aggregation 15 to 60 minutes after onset of treatment of 92% to 95% as measured with light transmission aggregometry (LTA).</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u><em>&nbsp; </em></p><p><em>&nbsp;</em></p><p>PRISM-PLUS study</p><p>The double-blind, multicentre, controlled PRISM-PLUS study compared the efficacy of Aggrastat and unfractionated heparin (n=773) versus unfractionated heparin (n=797) in patients with unstable angina (UA) or acute non-Q-wave myocardial infarction (NQWMI) with prolonged repetitive anginal pain or post-infarction angina, accompanied by new transient or persistent ST-T wave changes or elevated cardiac enzymes.&nbsp;</p><p>Patients were randomised to either Aggrastat (30 minute loading infusion of 0.4 microgram/kg/min followed by a maintenance infusion of 0.10 microgram/kg/min) and heparin (bolus of 5,000 units (U) followed by an infusion of 1,000 U/hr titrated to maintain an activated partial thromboplastin time (APTT) of approximately two times control), or heparin alone.&nbsp;</p><p>All patients received ASA unless contraindicated. Study drug was initiated within 12 hours after the last anginal episode. Patients were treated for 48 hours, after which they underwent angiography and possibly</p><p>angioplasty/atherectomy, if indicated, while Aggrastat was continued. Aggrastat was infused for a mean period of 71.3 hours.&nbsp;</p><p>The combined primary study end-point was the occurrence of refractory ischaemia, myocardial infarction or death at seven days after the start of Aggrastat.&nbsp;</p><p>At 7 days, the primary end-point, there was a 32% risk reduction (RR) (12.9% vs. 17.9%) in the Aggrastat group for the combined end-point (p=0.004): this represents approximately 50 events avoided for 1,000 patients treated. After 30 days the RR for the composite end-point of death, MI, refractory ischaemic conditions, or readmissions for UA was 22% (18.5% vs. 22.3%; p=0.029).&nbsp; After six months the relative risk of composite of death, MI, refractory ischaemic conditions, or readmissions for UA was reduced by 19% (27.7% vs. 32.1% ; p=0.024).&nbsp;</p><p>Regarding the,composite of death or MI, at seven days for the Aggrastat group there was a 43% RR (4.9% vs. 8.3%; p=0.006); at 30 days the RR was 30% (8.7% vs. 11.9%; p=0.027) and at 6 months the RR was 23% (12.3% vs.</p><p>15.3%; p=0.063).</p><p>The reduction of MI in patients receiving Aggrastat appeared early during treatment (within the first 48 hours) and was maintained through 6 months. In the 30% of patients who underwent angioplasty/atherectomy during initial hospitalisation, there was a 46% RR (8.8% vs. 15.2%) for the primary composite endpoint at 30 days as well as a 43% RR (5.9% vs. 10.2%) for death or MI.</p><p>&nbsp;</p><p>Based on a safety study, the concomitant administration of Aggrastat (30 minute loading dose of [0.4 microgram/kg/min] followed by a maintenance infusion of 0.1 microgram/kg/min for up to 108 hours) with enoxaparin (n=315) was compared to the concomitant administration of Aggrastat with unfractionated heparin (n=210) in patients presenting with UA and NQWMI.&nbsp; Patients in the enoxaparin group received a 1.0 milligram/kg subcutaneous injection every 12 hours for a period of at least 24 hours and a maximum duration of 96 hours. Patients randomised to unfractionated heparin received a 5000-unit intravenous bolus followed by a maintenance infusion of 1000 units per hour for at least 24 hours and a maximum duration of 108 hours. The total TIMI bleed rate was 3.5% for the Aggrastat/enoxaparin group and 4.8% for the Aggrastat/unfractionated heparin group. Although there was a significant difference in the rates of cutaneous bleeds between the two groups (29.2% in the enoxaparin converted to unfractionated heparin group and 15.2% in the unfractionated heparin group), there were no TIMI major bleeds (see section 4.4) in either group. The efficacy of Aggrastat in combination with enoxaparin has not been established.&nbsp;</p><p>&nbsp;</p><p>PRISM PLUS trial was conducted at a time when the standard of care of managing acute coronary syndromes was different from that of present times in terms of oral platelet ADP receptor (P2Y12) antagonists use and the routine use of intracoronary stents.</p><p><strong><em>&nbsp;</em></strong></p><p>ADVANCE study</p><p>The ADVANCE study determined the safety and efficacy of the Aggrastat 25 microgram/kg dose bolus regimen as compared with placebo in patients undergoing elective or urgent PCI who exhibit high-risk characteristics including the presence of at least one coronary narrowing &ge;70% and diabetes, need for multi-vessel intervention, or NSTEACS. All patients received unfractionated heparin, acetylsalicylic acid (ASA) and a thienopyridine loading dose followed by maintenance therapy.&nbsp; A total of 202 patients were randomised to either Aggrastat (25 microgram/kg bolus IV over 3 minutes followed by a continuous IV infusion of 0.15 microgram/kg/minute for 24-48 hours) or Placebo given immediately before PCI.&nbsp;</p><p>The primary endpoint was a composite of death, nonfatal MI, urgent target vessel revascularization (uTVR), or thrombotic bailout GP IIb/IIIa inhibitor therapy within a median follow-up of 180 days after the index procedure.</p><p>The safety endpoints of major and minor bleeding were defined according to the TIMI criteria.&nbsp;</p><p>In the intent-to-treat population, the cumulative incidence of the primary end point was 35% and 20% in placebo and Aggrastat groups, respectively (hazard ratio [HR] 0.51 [95% confidence interval (CI), 0.29 to 0.88]; p=0.01). As compared with placebo, there was a significant reduction in the composite of death, MI, or uTVR in the Aggrastat group (31% vs. 20%, HR, 0.57 95% CI, 0.99&ndash;0.33]; p=0.048.&nbsp;</p><p>&nbsp;</p><p>EVEREST study</p><p>The randomised open-label EVEREST trial compared the upstream 0.4 microgram/kg/min loading dose regimen initiated in the coronary care unit with the Aggrastat 25 microgram/kg dose bolus regimen or abciximab 0.25 milligram/kg initiated 10 minutes prior to PCI. All patients additionally received ASA and a thienopyridine. The 93 enrolled NSTE-ACS patients underwent angiography and PCI as appropriate, within 24-48 hours of admission. <strong>&nbsp;</strong>With respect to the primary endpoints of tissue level perfusion and troponin I release, the results of EVEREST determined significantly lower rates of post-PCI TMPG 0/1 (6.2% vs. 20% vs. 35.5%, respectively; p=0.015), and improved post-PCI MCE score index (0.88 &plusmn; 0.18 vs. 0.77 &plusmn; 0.32 vs. 0.71 &plusmn; 0.30, respectively; p&lt;0.05).</p><p>The incidence of post-procedural cardiac Troponin I (cTnI) elevation was significantly reduced in patients treated with the upstream Aggrastat regimen compared with PCI 25 microgram/kg dose bolus Aggrastat or abciximab</p><p>(9.4% vs. 30% vs. 38.7%, respectively; p=0.018). The cTnI levels post-PCI were also significantly decreased with the upstream regimen of Aggrastat compared with PCI Aggrastat (3.8 &plusmn; 4.1 vs. 7.2 &plusmn; 12; p=0.015) and abciximab (3.8 &plusmn; 4.1 vs. 9 &plusmn; 13.8; p=0.0002). The comparison between the PCI Aggrastat 25 microgram/kg dose bolus and abciximab regimens indicated no significant differences in the rate of TMPG 0/1 post-PCI (20% vs. 35%; p=NS).&nbsp;&nbsp;</p><p><strong><em>&nbsp;</em></strong></p><p>On-TIME 2 study</p><p>The On-TIME 2 trial was a multi-centre, prospective, randomised, controlled clinical trial which was designed to assess the effect of early upfront Aggrastat administration using the 25 microgram/kg dose bolus regimen in patients with STEMI planned for primary PCI. All patients received ASA, a 600 mg loading dose of clopidogrel, and unfractionated heparin. The use of bail-out Aggrastat was allowed according to pre-specified criteria. The study was accomplished in two phases: a pilot, open label phase (n=414) followed by a larger double-blind phase (n=984). A pooled analysis of data from both phases was pre-specified to evaluate the effect of the 25 microgram/kg dose bolus regimen compared to control as measured by a primary endpoint defined as the 30-day MACE rate (death, recurrent MI and uTVR).</p><p>In this pooled analysis, MACE at 30 days was significantly reduced by early upfront initiation of Aggrastat compared to control (5.8% vs. 8.6%; p=0.043). In addition, there was a strong trend toward a significant decrease in mortality with Aggrastat with respect to all-cause death (2.2% in the Aggrastat arm vs. 4.1% in the control arm; p=0.051). This mortality benefit was mainly due to a reduction of cardiac death (2.1% vs. 3.6%; p=0.086). At 1-year follow-up (the secondary endpoint), the mortality difference was maintained (3.7% vs. 5.8%; p=0.078 for all-cause mortality and 2.5% vs. 4.4% for cardiac mortality; p=0.061).&nbsp;</p><p>Patients who underwent primary PCI (86% of study population of pooled analysis) demonstrated a significant reduction in mortality both at 30 days (1.0% in the Aggrastat group vs. 3.9% in the control group; p=0.001) and at 1 year (2.4% for Aggrastat vs. 5.5% for control; p=0.007).</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p><p>MULTISTRATEGY study</p><p>The MULTISTRATEGY study was an open-label, 2X2 factorial, multinational trial which compared the Aggrastat (n=372) with abciximab (n=372) when used in conjunction with either a sirolimus-eluting (SES) or bare metal stent (BMS), in patients with STEMI. Either Aggrastat (bolus of 25 microgram/kg, followed by an infusion at 0.15 microgram/kg/min continued for 18 to 24 hours) or abciximab (bolus of 0.25 mg/kg, followed by a 12-hour infusion at 0.125 microgram/kg/min) was initiated before arterial sheath insertion during the angiography. All patients received unfractionated heparin, ASA and clopidogrel.&nbsp;</p><p>The primary endpoint for the drug comparison was cumulative ST-segment resolution expressed as the proportion of patients who achieve at least 50% recovery within 90 minutes after the last balloon inflation and tested the hypothesis that Aggrastat is noninferior to abciximab with respect to this endpoint.&nbsp;</p><p>In the intention-to-treat population, the percentage of patients with at least 50% recovery from ST-segment elevation was not significantly different between Aggrastat (85.3%) and abciximab (83.6%), demonstrating the non-inferiority of Aggrastat to abciximab (RR for Aggrastat vs. abciximab, 1.020; 97.5% CI, 0.958-1.086; p&lt;0.001 for noninferiority).&nbsp;</p><p>At 30 days, the rates of major adverse cardiac events (MACE) were similar for abciximab and Aggrastat (4.3% vs.</p><p>4.0%, respectively; p=0.85) with these results maintained at 8 months (12.4% vs. 9.9%, respectively; p=0.30).</p><p>&nbsp;</p><p>In On-TIME 2 and MULTISTRATEGY, patients were treated with dual oral antiplatelet therapy consisting of ASA and high-dose clopidogrel. The efficacy of Aggrastat in combination with either prasugrel or ticagrelor has not been established in randomised controlled trials.</p><p>&nbsp;</p><p>Meta-analysis of Randomised Trials of Aggrastat 25 microgram/kg Dose Bolus Regimen</p><p>The results of a meta-analysis evaluating the efficacy of the Aggrastat 25 microgram/kg dose bolus regimen versus abciximab (including 2213 ACS patients, across the ACS spectrum, with both NSTEMI and STEMI patients) did not reveal any significant difference in the OR for death or MI at 30 days between the two agents (OR, 0.87 [0.561.35]; p=0.54). Similarly, there were no significant differences in 30-day mortality between Aggrastat and abciximab (OR, 0.73 [0.36-1.47]; p=0.38). Additionally, at the longest follow-up, death or MI was not significantly different between Aggrastat and abciximab (OR, 0.84 [0.59-1.21]; p=0.35).&nbsp;</p><p>&nbsp;</p><p>TARGET study</p><p>In one study using a 10 microgram/kg bolus followed by a 0.15 microgram/kg/min infusion of Aggrastat, Aggrastat failed to demonstrate noninferiority to abciximab: the incidence of the composite primary endpoint (death, MI, or uTVR at 30 days) showed that abciximab was significantly more effective on clinically relevant endpoints, with 7.6% in the Aggrastat and 6.0% in the abciximab group (p=0.038), which was mainly due to a significant increase in the incidence of MI at 30 days (respectively 6.9% vs. 5.4%; p=0.04).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Distribution</p><p>Tirofiban is not strongly bound to plasma protein, and protein binding is concentration-independent in the range of 0.01&ndash;25 microgram/ml. The unbound fraction in human plasma is 35%.</p><p>&nbsp;</p><p>The distribution volume of tirofiban in the steady state is about 30 litres.</p><p>&nbsp;</p><p>Biotransformation</p><p>Experiments with <sup>14</sup>C-labelled tirofiban showed the radioactivity in urine and faeces to be emitted chiefly by unchanged tirofiban. The radioactivity in circulating plasma originates mainly from unchanged tirofiban (up to 10 hours after administration). These data suggested limited metabolisation of tirofiban.</p><p>&nbsp;</p><p>Elimination</p><p>After intravenous administration of <sup>14</sup>C-labelled tirofiban to healthy subjects, 66% of the radioactivity was recovered in the urine, 23% in the faeces. The total recovery of radioactivity was 91%. Renal and biliary excretion contribute significantly to the elimination of tirofiban.</p><p>&nbsp;</p><p>In healthy subjects the plasma clearance of tirofiban is about 250 ml/min. Renal clearance is 39&ndash;69% of plasma clearance.&nbsp; The half-life is about 1.5 hours.</p><p>&nbsp;</p><p><em>Gender </em></p><p>The plasma clearance of tirofiban in patients with coronary heart disease is similar in men and women.</p><p>&nbsp;</p><p>Elderly patients</p><p>The plasma clearance of tirofiban is about 25% less in elderly (&gt;65 years) patients with coronary heart disease in comparison to younger (65 years) patients.</p><p>&nbsp;</p><p><em>Ethnic groups </em></p><p>No difference was found in the plasma clearance between patients of different ethnic groups.</p><p>&nbsp;</p><p>Coronary Artery Disease</p><p>In patients with unstable angina pectoris or NQWMI the plasma clearance was about 200 ml/min, the renal clearance 39% of the plasma clearance. The half-life is about two hours.</p><p>&nbsp;</p><p>Impaired renal function</p><p>In clinical studies, patients with decreased renal function showed a reduced plasma clearance of tirofiban depending on the degree of impairment of creatinine clearance. In patients with a creatinine clearance of less than 30 ml/min, including haemodialysis patients, the plasma clearance of tirofiban is reduced to a clinically relevant extent (over 50%) (see section 4.2)<em>.</em> Tirofiban is removed by haemodialysis.</p><p>&nbsp;</p><p>Liver failure</p><p>There is no evidence of a clinically significant reduction of the plasma clearance of tirofiban in patients with mild to moderate liver failure. No data are available on patients with severe liver failure.</p><p>&nbsp;</p><p>Effects of other drugs</p><p>The plasma clearance of tirofiban in patients receiving one of the following drugs was compared to that in patients not receiving that drug in a sub-set of patients (n=762) in the PRISM study. There were no substantial (&gt;15%) effects of these drugs on the plasma clearance of tirofiban: acebutolol, alprazolam, amlodipine, aspirin preparations, atenolol, bromazepam, captopril, diazepam, digoxin, diltiazem, docusate sodium, enalapril, furosemide, glibenclamide, unfractionated heparin, insulin, isosorbide, lorazepam, lovastatin, metoclopramide, metoprolol, morphine, nifedipine, nitrate preparations, oxazepam, paracetamol, potassium chloride, propranolol, ranitidine, simvastatin, sucralfate and temazepam.</p><p>&nbsp;</p><p>The pharmacokinetics and pharmacodynamics of Aggrastat were investigated when concomitantly administered with enoxaparin (1 milligram/kg subcutaneously every 12 hours) and compared with the combination of Aggrastat and unfractionated heparin. There was no difference in the clearance of Aggrastat between the two groups.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity and genotoxicity.&nbsp;</p><p>&nbsp;</p><p>Fertility and reproductive performance were not affected in studies with male and female rats given intravenous doses of tirofiban hydrochloride up to 5 mg/kg/day. These dosages are approximately 22-fold higher than the maximum recommended daily dose in humans.</p><p>However, animal studies are insufficient to draw conclusions with respect to reproductive toxicity in humans.</p><p>&nbsp;</p><p>Tirofiban crosses the placenta in rats and rabbits.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sodium chloride, sodium citrate dihydrate, citric acid anhydrous, water for injection, hydrochloric acid and/or sodium hydroxide (for pH adjustment).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Incompatibility has been found with diazepam. Therefore, Aggrastat and diazepam should not be administered in the same intravenous line.</p><p>&nbsp;</p><p>No incompatibilities have been found with Aggrastat and the following intravenous formulations: atropine sulfate, dobutamine, dopamine, epinephrine HCl, furosemide, heparin, lidocaine, midazolam HCl, morphine sulfate, nitroglycerin, potassium chloride, propanolol HCl and famotidine injection.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years. 
From a microbiological point of view the diluted solution for infusion should be used immediately. If not used immediately, in use storage conditions are the responsibility of the user and would normally not be longer than 
24 hours at 2-8C, unless reconstitution has taken place in controlled and validated aseptic conditions. 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C. Do not freeze.&nbsp; Keep container in outer carton to protect from light.</p><p>&nbsp;</p><p>For storage conditions after dilution of the medicinal product, see section 6.3.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>50 ml Type I glass vial.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Aggrastat concentrate for solution for infusion must be diluted before use.&nbsp; See section 4.2.</p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                ALGORITHM S.A.L., Zouk Mosbeh, Lebanon 
Telephone: +961 9 222050  
Fax: +961 9 222141   
Email: www.algorithm-lb.com   

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                02/2018 
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>